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This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with
trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3þ primary breast cancer were
treated with trastuzumab plus docetaxel. Pathological complete and partial responses were documented for nine (39%) and 14
(61%) patients, respectively. Case-matched controls comprised patients treated with docetaxel-based PST without trastuzumab (D;
n¼23) or PST without docetaxel or trastuzumab (non-taxane, non-trastuzumab, NT–NT; n¼23). All surgical specimens were
blind-analysed by two independent pathologists, with immunohistochemical evaluation of B and T lymphocytes, macrophages,
dendritic cells and natural killer (NK) cells. Potential cytolytic cells were stained for Granzyme B and TiA1. HER2 expression was also
evaluated in residual tumour cells. Trastuzumab treatment was associated with significantly increased numbers of tumour-associated
NK cells and increased lymphocyte expression of Granzyme B and TiA1 compared with controls. This study supports an in vivo role
for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer. These results suggest that
trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and
docetaxel in breast cancer.
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The human epidermal growth factor receptor 2 (HER2) is a
member of the ErbB family that plays an important role in
promoting oncogenic transformation and tumour growth (Slamon
et al, 1987). Approximately 25–30% of patients with breast cancer
overexpress HER2 and this overexpression is correlated with gene
amplification and poor clinical outcome (King et al, 1985; Slamon
et al, 1987, 1989; van de Vijver et al, 1988; Gusterson et al, 1992;
Hynes and Stern, 1994).
Trastuzumab (Herceptin
s; F Hoffmann-La Roche, Basel,
Switzerland) selectively targets HER2 and is approved for the
treatment of women with HER2-overexpressing metastatic breast
cancer (MBC). Trastuzumab demonstrates favourable efficacy both
as a single agent (Cobleigh et al, 1999; Vogel et al, 2002) and in
combination with cytotoxic chemotherapy (Pegram et al, 1999;
Slamon et al, 2001; Marty et al, 2005). The proposed mechanisms
of action of trastuzumab include enhancement of HER2 degrada-
tion (Molina et al, 2001), inhibition of cell cycle progression via
inhibition of the mitogen-activated protein kinase pathway (Le
et al, 2003; Jackson et al, 2004), and suppression of the
antiapoptotic phosphatidylinositol 3-kinase and Akt pathways
(Yakes et al, 2002; Mohsin et al, 2005). In addition, there is
evidence supporting a role for trastuzumab in mediating antibody-
dependent cellular cytotoxicity (ADCC) (Cooley et al, 1999; Clynes
et al, 2000; Carson et al, 2001; Repka et al, 2003; Gennari et al,
2004). Mechanisms of action of trastuzumab demonstrated in vitro
in HER2-overexpressing cells are not always confirmed in in vivo
studies (Mohsin et al, 2005).
Trastuzumab-based therapy has been shown to be effective in
the neoadjuvant (primary systemic therapy (PST)) setting (Bines
et al, 2003; Burstein et al, 2003; Schiffhauer et al, 2003; Van Pelt
et al, 2003; Baselga et al, 2004; Buzdar et al, 2005). This
immunohistological analysis, which was undertaken as part of a
clinical study, aimed to evaluate the immune response to
trastuzumab-based PST within tumours obtained from women
with locally advanced breast cancer.
PATIENTS AND METHODS
Patients
Between March 2001 and December 2003, 33 women (age 18–65
years) with stage II/III, unilateral, non-inflammatory, operable
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the breast) were enrolled in the open-label, multicentre, phase II
TAXHER01 trial (Coudert et al, 2005). All patients had HER2-
positive (immunohistochemistry (IHC) 3þ or fluorescence in-situ
hybridisation (FISH)-positive) breast cancer and were treated with
PST consisting of six cycles of docetaxel (100mgm
 2 60-min
intravenous (i.v.) infusion every 3 weeks) and trastuzumab
(4mgkg
 1 90-min i.v. infusion 1 day before the first dose of
docetaxel, and thereafter at a dose of 2mgkg
 1 weekly for 17
weeks). All patients underwent surgery 3 weeks after the last cycle
of docetaxel and trastuzumab.
In all, 46 patients with breast cancer enrolled in the GIREC01
trial (Luporsi et al, 2000) were used as matched controls. Of these
patients, 23 received anthracycline-based, non-taxane, non-trastu-
zumab-containing PST (NT–NT; six cycles), and 23 received
docetaxel-based, non-trastuzumab-containing therapy (D; six
cycles). Tumours from 15 patients in the control group were
HER2 positive, five in the NT–NT group and 10 in the D group.
The treatment group (TAXHER01) was case-matched with the two
control groups in terms of pathologic tumour and node response.
Due to the lack of patients treated preoperatively with such a
combination, it was not possible to have control groups with
trastuzumab plus a non-taxane chemotherapy or trastuzumab
alone.
Both clinical studies were conducted in accordance with the
Helsinki Declaration and approved by an independent ethics
committee. Written informed consent was obtained from all
patients prior to enrolment.
Microscopic evaluation of the pathologic response to PST
Microtome sections obtained from surgical tissue were fixed in
10% neutral buffered formaldehyde solution or Bouin fluid
(Richard-Allan Scientific, Kalamazoo, MI, USA), embedded in
paraffin wax, and stained with haematoxylin, eosin, and saffron.
Pathologic response to PST was assessed according to the Sataloff
classification (Sataloff et al, 1995). Tumour samples containing no
tumour nodules or tumours with residual area o2mm in diameter
were classified as TA. Tumour samples with residual tumour area
o0.2mm in diameter in lymph nodes, not classified as micro-
metastases in the UCC classification (Singletary et al, 2002;
Singletary and Greene, 2003), were classified as NA.
Microscopic and immunohistologic analyses
Immunohistochemical evaluation was performed on one paraffin
block that was considered to correspond morphologically with the
tumour response area, using the biotin–streptavidin complex
(ABC) technique (StreptABC complex/HRP Duet; Dako, Glostrup,
Denmark) and the following primary antibodies: B lymphocytes
(CD20 (L26, 1 out of 50; Dako, Glostrup, Denmark)); T lympho-
cytes (CD3 (F7.2.38, 1 out of 25; Dako, Glostrup, Denmark); CD4
(NCL-CD4-368, 1 out of 150; Novocastra, Newcastle, UK); CD8
(C8/144B, 1 out of 25; Dako, Glostrup, Denmark)); macrophages
(CD68 (PG-M1, 1 out of 50; Dako, Glostrup, Denmark)); dendritic
cells (PS100 (S100, 1 out of 500; Dako, Glostrup, Denmark); CD1a
(010, 1 out of 40; Dako, Glostrup, Denmark)); HLA-DR-expressing
cells (HLA-DR (TAL.1B5, 1 out of 20;Dako, Glostrup, Denmark))
and natural killer (NK) cells (CD56 (1B6, 1 out of 50; Novocastra,
Newcastle, UK); NK1 (NK1, 1 out of 75; Dako, Glostrup,
Denmark)). Potential cytolytic cells were stained with Granzyme
B (GrB-7, 1 out of 25; Dako, Glostrup, Denmark) and TiA1 (2G9, 1
out of 50; Immunotech, Marseille, France). TiA1 is a 17kDa
cytoplasmic granule-associated protein expressed in cells posses-
sing, like Granzyme B-expressing cells, potential cytolytic activity.
If residual tumour cells were identified, immunohistochemical
analysis of HER2 expression was performed (A485, 1 out of 1600;
Dako, Glostrup, Denmark).
Two pathologists, blinded to study treatment, performed
independent IHC evaluations of all tumour samples. Infiltrating
cells were analysed in four separate locations on each slide: diffuse
(isolated cells distributed all around the area of tumour regres-
sion), foci (organised in nodules), around (a small rim around the
tumour nodules in contact with residual tumour cells), and inside
(penetrating inside tumour nodules between residual tumour
cells). In each location on the slide, the number of stained cells was
analysed using a semiquantitative ordinal scale ranging from 0 to 4
(0, þ/ , þþ, þþþ). For each antibody, this scale was
established after the analysis of more than 15 cases and concerned
only the number of infiltrating stained cells, whatever the intensity
of the staining. The results of the analyses conducted by each
independent pathologist were subsequently compared. For each
location, all cases in which scores differed by more than one point
on the semiquantitative scale were re-examined and a consensus
score was reached.
Statistical analysis
Slides were unblinded immediately prior to the statistical analysis.
Statistical analyses were performed with a 5% type I (bilateral)
error using the Stata 8.2 software package (StataCorp LP, TX,
USA). The mean (standard deviation (s.d.)) number of stained
cells was calculated for each data group (treatment group and
two control groups). A two-sided Wilcoxon rank-sum (Mann–
Whitney) test was used to determine differences between the
groups.
A subgroup analysis was also performed to exclude potential
treatment-independent, HER2 overexpression-related effects if
values obtained for the treatment and control groups were
significantly different. This analysis compared the results from
the treatment group (TAXHER01) with those from HER2-over-
expressing subgroups of the control groups (HER2 control,
n¼15). Due to multiple testing, a type I error adjustment was
applied to this subgroup analysis (significance level Pp0.01).
RESULTS
Three patients from the TAXHER01 trial withdrew from the study
due to toxicity. Seven additional cases were not available for
immunohistochemical analysis because of fixative problems or
Table 1 Patient characteristics
TAXHER01
(N¼23) NT-NT (N¼23) D (N¼23)
Age, mean (range) 45 (24–64) 44.5 (27–60) 47.5 (27–65)
Clinical tumour stage
T2 14 16 13
T3 9 7 10
Clinical nodal status
N0 10 10 10
N1 13 13 13
Scarff-Bloom-Richardson tumour grade
I1 3 1
II 9 9 8
III 13 11 14
Tumour hormone-receptor status
Positive 13 12 13
Negative 10 11 10
NT-NT¼non-taxane, non-trastuzumab; D¼docetaxel.
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TAXHER01 (n¼23) Control (n¼46) D (n¼23) NT–NT (n¼23) TAXHER01 vs control D vs NT–NT
Antibodies location Mean (s.d.) staining intensity score P-value
CD20
Diffuse 1.61 (1.3) 1.10 (0.9) 1.09 (0.9) 1.04 (0.9) 0.0802 0.8272
Around 1.13 (1.5) 0.52 (1.2) 0.39 (1.0) 0.65 (1.3) 0.0598 0.4432
Inside 0.43 (0.9) 0.33 (0.9) 0.04 (0.1) 0.61 (1.2) 0.4013 0.0686
Foci 3.13 (1.2) 1.70 (1.5) 1.61 (1.4) 1.78 (1.7) 0.0005 0.8391
CD3
Diffuse 2.09 (1.4) 1.42 (1.0) 1.35 (0.9) 1.50 (1.1) 0.0386 0.7389
Around 1.52 (1.6) 0.82 (1.5) 0.70 (1.4) 0.95 (1.5) 0.0560 0.5014
Inside 0.65 (1.2) 0.47 (1.0) 0.39 (0.9) 0.55 (1.1) 0.4734 0.5014
Foci 2.87 (1.1) 1.64 (1.2) 1.43 (1.1) 1.86 (1.4) 0.0001 0.2116
CD4
Diffuse 1.04 (1.3) 0.91 (0.9) 0.91 (0.8) 0.91 (0.9) 0.7605 0.8776
Around 1.35 (1.7) 0.46 (1.0) 0.39 (1.0) 0.52 (1.1) 0.0270 0.5223
Inside 0.35 (0.7) 0.04 (0.2) 0.00 (0.0) 0.09 (0.3) 0.0209 0.1527
Foci 2.17 (1.3) 1.30 (1.3) 1.65 (1.2) 0.96 (1.3) 0.0107 0.0627
CD8
Diffuse 1.96 (1.5) 1.87 (0.9) 1.96 (0.9) 1.78 (1.0) 0.5670 0.4738
Around 1.56 (1.7) 0.76 (1.4) 0.52 (1.2) 1.00 (1.5) 0.0460 0.1997
Inside 1.22 (1.3) 0.78 (1.1) 0.65 (1.1) 0.91 (1.0) 0.1999 0.2454
Foci 2.39 (1.6) 1.50 (1.4) 1.43 (1.3) 1.56 (1.5) 0.0160 0.6410
CD68
Diffuse 1.91 (1.3) 2.30 (1.2) 2.43 (1.2) 2.17 (1.2) 0.3036 0.5172
Around 0.91 (1.6) 0.54 (1.3) 0.48 (1.3) 0.61 (1.3) 0.3594 0.5271
Inside 0.56 (1.0) 0.39 (0.8) 0.26 (0.7) 0.52 (0.8) 0.5676 0.1883
Foci 0.09 (0.4) 0.00 (0.0) 0.00 (0.0) 0.00 (0.0) 0.1573
PS100
Diffuse 1.70 (1.3) 1.59 (1.2) 1.48 (0.9) 1.70 (1.5) 0.7068 0.9540
Around 1.35 (1.6) 0.63 (1.3) 0.30 (0.9) 0.96 (1.5) 0.0557 0.1234
Inside 0.61 (1.3) 0.37 (0.9) 0.13 (0.6) 0.61 (1.1) 0.4579 0.0488
Foci 1.74 (1.7) 1.1 (1.4) 0.78 (1.2) 1.35 (1.6) 0.0691 0.2202
CD1a
Diffuse 1.61 (0.8) 1.83 (0.9) 1.74 (0.8) 1.91 (0.9) 0.3788 0.4385
Around 0.39 (0.7) 0.41 (1.0) 0.39 (1.0) 0.43 (1.0) 0.5556 0.5378
Inside 0.26 (0.5) 0.28 (0.9) 0.17 (0.7) 0.39 (1.0) 0.3180 0.5968
Foci 0.00 (0.0) 0.00 (0.0) 0.00 (0.0) 0.00 (0.0)
HLA-DR
Diffuse 2.09 (1.0) 2.33 (1.0) 2.26 (0.8) 2.39 (1.1) 0.5370 0.4624
Around 1.70 (1.7) 1.04 (1.5) 0.83 (1.5) 1.26 (1.5) 0.1151 0.2308
Inside 0.91 (1.2) 0.72 (1.0) 0.39 (0.8) 1.04 (1.1) 0.5778 0.0258
Foci 2.30 (1.1) 1.54 (1.3) 1.70 (1.3) 1.39 (1.3) 0.0335 0.4649
CD56
a
Diffuse 0.83 (1.0) 0.74 (0.8) 0.87 (0.8) 0.61 (0.8) 1.0000 0.2125
Around 1.00 (1.5) 0.57 (1.1) 0.43 (1.0) 0.70 (1.2) 0.2468
a 0.3175
Inside 0.30 (0.7) 0.11 (0.4) 0.09 (0.4) 0.13 (0.3) 0.2520
a 0.3336
Foci 0.26 (0.7) 0.28 (0.8) 0.26 (0.9) 0.30 (0.7) 0.9739 0.4756
NK1
Diffuse 1.45 (1.4) 1.20 (0.9) 1.39 (0.8) 1.00 (0.9) 0.5864 0.1349
Around 1.64 (1.6) 0.41 (1.0) 0.43 (1.1) 0.39 (1.0) 0.0003 0.7919
Inside 0.82 (1.3) 0.30 (0.8) 0.17 (0.7) 0.43 (1.0) 0.0438 0.2251
Foci 2.01 (1.4) 0.74 (1.1) 0.83 (1.1) 0.65 (1.1) 0.0003 0.4678
TiA1
Diffuse 1.13 (1.3) 1.30 (1.0) 1.30 (0.9) 1.30 (1.1) 0.4411 0.9816
Around 1.43 (1.7) 0.85 (1.5) 0.61 (1.4) 1.1 (1.6) 0.1982 0.3113
Inside 0.65 (1.0) 0.26 (0.8) 0.17 (0.7) 0.35 (0.9) 0.0370 0.3878
Foci 1.00 (1.0) 0.54 (1.0) 0.65 (1.2) 0.43 (0.8) 0.2181 0.5759
Granzyme B
Diffuse 0.26 (0.7) 0.26 (0.4) 0.30 (0.5) 0.22 (0.4) 0.4870 0.5066
Around 0.83 (1.3) 0.28 (0.9) 0.22 (0.9) 0.35 (0.9) 0.0324 0.4087
Inside 0.22 (0.7) 0.07 (0.3) 0.13 (0.5) 0.00 (0.0) 0.1926 0.1528
Foci 0.52 (0.8) 0.33 (0.7) 0.13 (0.3) 0.52 (0.9) 0.2571 0.1126
NT–NT, anthracycline-based PST that does not include a taxane or trastuzumab; D, docetaxel-based PST. For diffuse/around/inside/foci, scores range from 0 to 4.
aStaining with
CD56 was less intense and difficult to quantify. Significant if Po0.05. Bold values signify their importance in the results and the discussion.
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sfalse-positive HER2 overexpression. The final analysis was there-
fore performed on the surgical specimens from 23 patients. The
control group from the GIREC01 trial comprised specimens
obtained from 46 (23 NT–NT and 23 D) patients, 15 of whom
had tumours that were HER2 positive (5 NT–NT and 10 D).
Patient characteristic data are shown in Table 1.
Pathologic response
After surgery, nine tumours in the TAXHER01 group (39%) were
classified as demonstrating a pathological complete response
(pCR; TA/NA or TA/NB), with two demonstrating residual tumour
aggregates o2mm in diameter. One other tumour was classified as
TA/NC (no residual tumour in the breast, but residual tumour cells
in the lymph nodes). The remaining 13 tumours displayed partial
(pPR; TB or TC) or absent (TD) pathological responses. Eight
tumours were classified as TB (residual tumour size 0.4–1.5cm
(mean 0.80cm)), four were classified as TC (residual tumour size
1.5–7.0cm (mean 3.2cm)), and only one tumour was classified as
TD (residual tumour size 6cm). As tumour responses in the two
control groups were matched to those in the treatment group,
there were equivalent numbers of patients with complete, partial,
or absent pathological responses in the 23 tumours treated in the D
and NT–NT groups.
Areas of tumour response were associated with fibrosis,
myxoedema, and macrophage/lymphocyte infiltration. Necrosis
or infiltration with polynuclear neutrophils was not observed.
Immunohistochemical analysis
Immune cell infiltration Comparison of the three groups revealed
that higher expression of PS100 and HLA-DR was observed in the
TAXHER01 and NT–NT groups as compared with the D group,
although the difference was not statistically significant (Table 2).
Comparison of pooled results from the D and NT–NT groups
with TAXHER01 showed greater numbers of immunocompetent
cells in the TAXHER01 specimens compared with controls. B
lymphocytes were more numerous in the TAXHER01 specimens at
the four locations analysed, but the difference was only significant
in the foci infiltrates. T lymphocytes (CD3, CD4, and CD8) were
also more numerous in the TAXHER01 specimens; differences
between TAXHER01 and control specimens were statistically
significant in the diffuse and foci infiltrates for CD3, in the foci,
inside and around infiltrates for CD4, and in the foci and around
infiltrates for CD8. Tumour area infiltration by macrophages
(CD68) was not statistically different between the TAXHER01 and
Figure 1 Immunohistochemical staining with NK1. Residual tumour from
the TAXHER01 group (A) and from a matched tumour treated in the
control group (B), both stained with NK1. The tumours of the TAXHER01
group show more cells in contact with or close to the tumour cells.
Figure 2 Immunohistochemical staining with CD56. Residual tumour
from the TAXHER01 group (A) and from a matched tumour treated in
the control group (B) both stained with CD56. The tumours of the
TAXHER01 group show more cells in contact with or close to the tumour
cells.
In-vivo evidence of ADCC role in trastuzumab MoA
L Arnould et al
262
British Journal of Cancer (2006) 94(2), 259–267 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scontrol groups. Dendritic cells (PS100, CD1a) and HLA-DR-
expressing inflammatory cells appeared to be slightly more
abundant in the TAXHER01 samples, but, because of the
differences between the two control groups, results are difficult
to interpret (Table 2). Figures 1–4 show immunohistochemical
staining of cells that are able to undergo ADCC mechanisms, and
that have potential cytotoxic activity, from both the TAXHER01
group and the case-matched control groups. Natural killer cell
numbers were increased in the around (Figure 1A) and inside
infiltrates of residual tumour cells in TAXHER01 specimens
compared with controls (statistically significant by NK1 staining,
Figure 1). In addition, there were statistically more NK1-positive
cells in foci infiltrates from TAXHER01 specimens compared with
controls. Staining with CD56 is notoriously difficult and was
therefore less intense than other methods and consequently
difficult to quantify (Figure 2). Finally, cytotoxic molecule
(Granzymze B and TiA1)-expressing cells were more numerous
in contact with the residual tumour cells in TAXHER01 specimens
compared with controls (Figures 3 and 4), with statistically
significant differences demonstrated for Granzyme B (around)
and for TiA1 (inside).
Influence of HER2 overexpression on immune cell infiltration To
evaluate the potential treatment-independent effects of HER2
overexpression, immune cell infiltration in TAXHER01 tumours
was compared with that in HER2-positive tumour subgroups of
the control groups (HER2 control, n¼15) (Table 3). While the
number of cases in the HER2-positive tumour subgroup is low, the
comparison between the TAXHER01 treatment group and this
subgroup is favoured as these tumour samples were obtained
from a clinical trial and hence had validated clinical and
pathological data.
The limited number of cases in this subanalysis precludes
definitive conclusions. There was a trend towards increased
lymphocyte numbers (CD20, CD3, CD4, and CD8) in the
TAXHER01 group compared with HER2 controls. Diffuse macro-
phage infiltration (CD68) was significantly increased in HER2
controls compared with the treatment group, but increased
macrophage infiltration was observed around the residual tumours
in the treatment group. There was also a trend towards increased
dendritic cell (PS100, CD1a) and HLA-DR-expressing cell infiltra-
tion in TAXHER01 tumours. Natural killer and cytotoxic cells
(TiA1 or Granzyme B) tended to be more numerous in contact
with residual tumour cells in the TAXHER01 tumours, with
significant differences demonstrated for TiA1 (Po0.05) and NK1
staining (Po0.01).
Figure 3 Immunohistochemical staining with Granzyme B. Residual
tumour from the TAXHER01 group (A) and from a matched tumour
treated in the control group (B), both stained with Granzyme B. The
tumours of the TAXHER01 group show more cells in contact with or close
to the tumour cells.
Figure 4 Immunohistochemical staining with TiA1. Residual tumour
from the TAXHER01 group (A) and from a matched tumour treated in the
control group (B), both stained with TiA1. The tumours of the TAXHER01
group show more cells in contact with or close to the tumour cells.
In-vivo evidence of ADCC role in trastuzumab MoA
L Arnould et al
263
British Journal of Cancer (2006) 94(2), 259–267 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sCorrelation of tumour response with level of immune cell
infiltration To further characterise the role of immune cells on
tumour regression, immune cell infiltration in TAXHER01
tumours demonstrating a partial response (TB) was compared
with that in TAXHER01 tumours demonstrating a poor or absent
response (TC and TD). For almost all markers (except CD8, CD68,
and PS100), there was a trend towards increased cell infiltration in
responsive tumours (Table 4). This was particularly evident for NK
(CD56 and NK1) and cytotoxic markers (Granzyme B and TiA1)
inside residual tumour aggregates. With the exception of TiA1,
these differences were not statistically significant.
HER2 expression on residual tumour cells At the time of surgery,
HER2 overexpression was unaffected by trastuzumab treatment,
with pre- and posttreatment biopsies demonstrating strong A485
staining on tumour cell membranes.
DISCUSSION
Approximately 20–30% of all breast cancers overexpress HER2
(Slamon et al, 1987; van de Vijver et al, 1988; Ross et al, 2003;
Owens et al, 2004). Targeted treatment of HER2-positive meta-
static breast cancer (MBC) with single-agent trastuzumab demon-
strates favourable efficacy (Cobleigh et al, 1999; Vogel et al, 2002),
and efficacy is enhanced by combination with cytotoxic chemo-
therapy (Slamon et al, 2001; Marty et al, 2005). Indeed,
combination treatment with trastuzumab and cytotoxic chemo-
therapy is now used as standard therapy for HER2-positive MBC.
Trastuzumab is thought to have a diverse and complex mechanism
of action. As trastuzumab is a monoclonal antibody that binds to
the surfaces of HER2-overexpressing cancer cells, it has been
postulated that ADCC may play an important role in the
mechanism of action of this drug (Cooley et al, 1999; Clynes
et al, 2000; Carson et al, 2001; Repka et al, 2003; Gennari et al,
2004). The current in vivo study was undertaken to analyse the
potential role of different immune cells in the clinical response to
trastuzumab.
Pre- and postoperative breast tissue samples were obtained from
patients with HER2-overexpressing advanced breast cancer
participating in a clinical trial of a neoadjuvant regimen
incorporating trastuzumab and docetaxel. This treatment strategy
is associated with a high pathologic response rate (Coudert et al,
2005), which is in accordance with the good efficacy previously
reported for the combination of paclitaxel and trastuzumab in this
setting (Bines et al, 2003; Burstein et al, 2003; Schiffhauer et al,
2003; Van Pelt et al, 2003; Baselga et al, 2004). In order to discount
the effects of intratumoural immune cell modifications that may be
induced by conventional chemotherapy drugs, the control group
comprised tumours from patients treated with two different PST
Table 3 Immune cell infiltration into HER2-overexpressing breast
tumours following PST
TAXHER01
(n¼23)
HER2 control
(n¼15) TAXHER01 vs
control
Antibodies
location
Mean (s.d.) staining intensity
score P-value
CD20
Diffuse 1.61 (1.27) 1.53 (1.19) 0.8525
Around 1.13 (1.52) 0.40 (1.06) 0.1036
Inside 0.43 (0.94) 0.20 (0.77) 0.2488
Foci 3.13 (1.18) 2.13 (1.64) 0.0840
CD3
Diffuse 2.09 (1.41) 1.80 (1.08) 0.3734
Around 1.52 (1.62) 0.93 (1.44) 0.2352
Inside 0.65 (1.19) 0.40 (0.74) 0.6948
Foci 2.87 (1.06) 1.67 (1.40) 0.0046
CD4
Diffuse 1.04 (1.33) 0.87 (0.91) 0.9618
Around 1.35 (1.67) 0.33 (0.72) 0.0605
Inside 0.35 (0.71) 0.00 (0.00) 0.0565
Foci 2.17 (1.27) 1.53 (1.30) 0.1423
CD8
Diffuse 1.96 (1.49) 2.00 (1.00) 0.9259
Around 1.56 (1.70) 0.80 (1.21) 0.1342
Inside 1.22 (1.31) 0.67 (0.90) 0.2039
Foci 2.39 (1.62) 2.33 (1.17) 0.5882
CD68
Diffuse 1.91 (1.31) 3.13 (0.74) 0.0037
Around 0.91 (1.59) 0.00 (0.00) 0.0341
Inside 0.56 (0.99) 0.33 (0.72) 0.5592
Foci 0.09 (0.42) 0.00 (0.00) 0.4193
PS100
Diffuse 1.70 (1.29) 2.00 (1.07) 0.4600
Around 1.35 (1.64) 0.67 (1.29) 0.2253
Inside 0.61 (1.31) 0.20 (1.56) 0.4394
Foci 1.74 (1.66) 1.27 (1.53) 0.3246
CD1a
Diffuse 1.61 (0.78) 1.80 (0.77) 0.4990
Around 0.39 (0.72) 0.40 (0.91) 0.7634
Inside 0.26 (0.54) 0.27 (0.80) 0.5800
Foci 0.00 (0.00) 0.00 (0.00)
HLA-DR
Diffuse 2.09 (1.04) 2.40 (0.91) 0.5216
Around 1.69 (1.72) 0.73 (1.33) 0.0786
Inside 0.91 (1.16) 0.53 (0.92) 0.3676
Foci 2.30 (1.15) 2.00 (1.20) 0.5809
CD56
a
Diffuse 0.83 (1.03) 0.67 (0.82) 0.7562
Around 1.00 (1.51) 0.80 (1.08) 0.8762
Inside 0.30 (0.70) 0.20 (0.56) 0.7062
Foci 0.26 (0.69) 0.53 (1.12) 0.4797
NK1
Diffuse 1.45 (1.40) 1.20 (0.86) 0.5737
Around 1.64 (1.56) 0.40 (1.12) 0.0097
Inside 0.82 (1.26) 0.20 (0.77) 0.0532
Foci 2.05 (1.43) 1.07 (1.16) 0.0303
TiA1
Diffuse 1.13 (1.32) 1.67 (0.82) 0.1448
Around 1.43 (1.73) 0.53 (1.41) 0.0942
Inside 0.65 (1.03) 0.07 (0.26) 0.0407
Foci 1.00 (1.20) 1.00 (1.51) 0.8120
Table 3 (Continued)
TAXHER01
(n¼23)
HER2 control
(n¼15) TAXHER01 vs
control
Antibodies
location
Mean (s.d.) staining intensity
score P-value
Granzyme B
Diffuse 0.26 (0.69) 0.33 (0.49) 0.3126
Around 0.82 (1.33) 0.27 (0.80) 0.1374
Inside 0.22 (0.67) 0.07 (0.26) 0.5188
Foci 0.52 (0.85) 0.27 (0.80) 0.1758
NT–NT, anthracycline-based PST that does not include a taxane or trastuzumab; D,
docetaxel-based PST. For diffuse/around/inside/foci, scores range from 0 to 4.
aStaining with CD56 was less intense and difficult to quantify. Significant if Po0.05.
Bold values signify their importance in the results and the discussion.
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control groups were matched in respect of pathologic response to
eliminate the effects of intratumoral immune cell modifications
induced by the response itself. This is the first time a comparison
of this type has been reported.
The results of this study demonstrate that the inclusion of
trastuzumab in the PST regimen influences the number and
topography of various immune cells, including T and B
lymphocytes and NK cells, in tumour infiltrates. Natural killer
cells are able to kill cells that are coated with an antibody via an
ADCC mechanism (Clynes et al, 2000). The presence of increased
numbers of NK cells in tumour infiltrates after trastuzumab
treatment, as well as the presence of cytotoxic proteins such as
Granzyme B, lends support to a role for NK cells in trastuzumab-
induced tumour regression. Increased numbers of NK cells are also
seen in tumours demonstrating an incomplete but pathologically
important response (TB) compared with those showing a poor or
absent pathologic response (TC or TD). The persistence of HER2
overexpression confirms that trastuzumab-mediated ADCC is a
feasible mechanism of action for the drug.
Two in vivo pilot studies have evaluated the potential role of
ADCC in the mechanism(s) of action of trastuzumab. Repka et al
(2003) demonstrated that treatment with a combination of
trastuzumab and interleukin-2 led to NK cell expansion and NK
cell-mediated ADCC against HER2-overexpressing cells. Addition-
ally, they showed that serum from treated patients had residual
ADCC activity 2–8 weeks after the last trastuzumab injection.
Gennari et al (2004) showed that peripheral blood mononuclear
cells of trastuzumab-treated patients demonstrated in vitro
cytopathic activity against HER2-overexpressing cells, with ADCC
activity more pronounced in tumours demonstrating a good
response to treatment compared with those exhibiting a poor
response. In common with the present study, Gennari did not
observe downregulation of HER2 expression after treatment,
although they were able to demonstrate that residual tumour cells
were still coated with trastuzumab at the time of the surgery as well
as an increase in NK-rich lymphoid infiltration, but were unable to
attribute this increase to the type of treatment or to the regression
itself.
Further support for a role for ADCC in the mechanism of action
of trastuzumab has emerged from in vivo xenograft (Clynes et al,
2000) and in vitro studies (Cooley et al, 1999; Carson et al, 2001;
Kubo et al, 2003), which have demonstrated that NK cells are able
to kill trastuzumab-coated HER2-overexpressing cells via a FcgRIII
receptor (CD16)-mediated ADCC mechanism. Yamaguchi et al
(2005) also demonstrated that lymphokine-activated killer cell
cytotoxic activity against HER2-positive breast cancer cell lines
MDA-MB453 and ZR75-1 was significantly increased in the
presence of 10nM trastuzumab. These data, together with the
current data, lend support to the evaluation of combination
Table 4 Immune cell infiltration into breast tumours following
trastuzumab-based PST by response status
TAXHER01 TB
(n¼8)
TAXHER01 TC/
TD (n¼5)
Antibodies
location
Mean (s.d.) staining intensity
score P-value
CD20
Diffuse 1.50 (1.51) 1.40 (1.14) 1.0000
Around 2.75 (1.28) 0.8 (1.10) 0.0187
Inside 1.13 (1.36) 0.20 (0.45) 0.2090
Foci 3.63 (0.52) 3.40 (0.89) 0.7339
CD3
Diffuse 1.50 (1.41) 1.60 (1.52) 0.9381
Around 3.25 (0.71) 1.80 (1.30) 0.0362
Inside 1.75 (1.49) 0.20 (0.45) 0.0437
Foci 3.00 (0.76) 3.20 (0.45) 0.6134
CD4
Diffuse 0.88 (1.64) 0.60 (1.34) 0.7659
Around 2.75 (1.49) 1.80 (1.64) 0.1852
Inside 0.75 (1.04) 0.40 (0.55) 0.6737
Foci 2.50 (1.31) 2.80 (0.84) 0.9364
CD8
Diffuse 2.13 (1.36) 0.80 (1.79) 0.2037
Around 2.88 (1.25) 2.60 (1.52) 0.7362
Inside 1.75 (1.04) 2.80 (0.45) 0.0503
Foci 2.38 (1.69) 2.00 (1.87) 0.7045
CD68
Diffuse 0.88 (1.25) 2.40 (1.34) 0.0467
Around 2.13 (1.81) 0.80 (1.79) 0.2590
Inside 0.88 (1.25) 1.20 (1.10) 0.6215
Foci 0.25 (0.71) 0.00 (0.00) 0.4292
PS100
Diffuse 1.50 (1.51) 2.20 (1.30) 0.3635
Around 2.25 (1.58) 2.60 (1.52) 0.6471
Inside 1.50 (1.85) 0.40 (0.89) 0.2418
Foci 1.75 (1.91) 2.60 (1.52) 0.5323
CD1a
Diffuse 1.50 (0.93) 1.20 (0.45) 0.4666
Around 0.88 (0.83) 0.40 (0.89) 0.2590
Inside 0.63 (0.74) 0.20 (0.45) 0.2693
Foci 0.00 (0.00) 0.00 (0.00)
HLA-DR
Diffuse 2.00 (1.31) 2.00 (1.22) 0.8750
Around 3.13 (1.36) 2.80 (0.45) 0.1454
Inside 1.75 (1.04) 1.40 (1.34) 0.6471
Foci 2.50 (1.31) 2.60 (0.55) 1.0000
CD56
a
Diffuse 0.75 (1.16) 0.40 (0.89) 0.5306
Around 2.25 (1.67) 1.00 (1.41) 0.1460
Inside 0.88 (0.99) 0.00 (0.00) 0.0714
Foci 0.00 (0.00) 0.40 (0.89) 0.2059
NK1
Diffuse 0.57 (1.13) 1.00 (1.41) 0.6282
Around 3.00 (1.41) 2.20 (0.84) 0.1063
Inside 1.29 (1.50) 1.20 (1.30) 1.0000
Foci 2.71 (1.38) 2.00 (1.22) 0.2332
TiA1
Diffuse 0.63 (1.19) 1.00 (1.41) 0.5902
Around 3.13 (1.36) 1.60 (1.52) 0.0456
Inside 1.50 (1.20) 0.60 (0.89) 0.1697
Foci 0.50 (1.41) 0.60 (1.34) 0.8160
Table 4 (Continued)
TAXHER01 TB
(n¼8)
TAXHER01 TC/
TD (n¼5)
Antibodies
location
Mean (s.d.) staining intensity
score P-value
Granzyme B
Diffuse 0.50 (1.07) 0.20 (0.45) 0.7659
Around 2.00 (1.60) 0.60 (0.89) 0.1107
Inside 0.63 (1.06) 0.00 (0.00) 0.1366
Foci 0.25 (0.71) 0.80 (1.30) 0.2762
For diffuse/around/inside/foci, scores range from 0 to 4.
aStaining with CD56 was less
intense and difficult to quantify. Significant if Po0.01 (multiple testing adjustment).
Bold values signify their importance in the results and the discussion.
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interleukin-2 (Fleming et al, 2002; Repka et al, 2003), as well as the
construction of bispecific antibodies targeting HER2 and CD16
(Shahied et al, 2004).
Trastuzumab plus docetaxel is an approved and well-tolerated
anticancer regimen that is used worldwide for the treatment of
HER2-positive MBC. Taxanes, especially docetaxel, lead to
increased serum concentrations of some cytokines and enhance-
ment of NK cell activity (Tsavaris et al, 2002). The current study
confirms that NK cytotoxicity via ADCC is probably one of the
mechanisms of action of trastuzumab and demonstrates increased
numbers of NK cells in tumours treated with docetaxel and
trastuzumab compared with docetaxel alone. These findings may
partially explain the synergistic activity of trastuzumab and
docetaxel in the treatment of HER2-positive breast cancer and
the excellent clinical outcomes afforded by this combination. In
the TAXHER01 study (Coudert et al, 2005), tumours that were
centrally confirmed to be HER2 positive displayed a pCR of 54%.
This is superior to that observed with non-trastuzumab-containing
neoadjuvant regimens in unselected patient populations. The
results of this immunohistochemical study may also have
implications for the design of future clinical trials involving
trastuzumab. Perceived trastuzumab activity may be damaged by
association with therapies that have immunosuppressive proper-
ties. An interesting area for future investigation could be
combination therapy with trastuzumab, chemotherapy and im-
munomodulators, for example, co-administration of NK cells
and/or cytokine injections.
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